Brazilian health officials said on Tuesday that the effectiveness of the COVID-19 vaccine produced in China in preventing infection is slightly higher than 50%, which is higher than the World Health Organization (WHO) vaccine effectiveness benchmark standard, but far lower than those produced in Western countries. Kind of vaccine.
The New York Times reported that the results of a survey released by the Bataan Institute in Sao Paulo showed that the CoronaVac injection produced by Sinovac is far less efficient than competing products produced by Moderna, Pfizer and AstraZeneca.
The actual efficiency is far below the level of the Sinova candidate estimated by officials. According to reports last week, São Paulo officials estimated that CoronaVac is 78% effective in preventing COVID-1
The difference seems to lie in data collection, because the data released last week did not count patients who experienced “very mild” coronavirus infections after receiving the injection.
Overall, the Butantan Institute found that CoronaVac is still 100% effective in preventing “severe” or “moderate” coronavirus infections, while mild or very mild infections may still occur after the injection.
The lower efficiency of Sinovac candidates may lead to lower demand for Chinese public health advocacy experts; the Chinese government has sought to establish closer ties with countries around the world through its vaccine distribution plan.
In recent weeks, China has been accelerating the promotion of its vaccine and announced that it will vaccinate 50 million people within its borders by January 15 so that many people will be vaccinated a second time before the Lunar New Year celebrations begin.
The second candidate vaccine produced by Sinopharm Group in China was judged by health officials in the United Arab Emirates as having an effective rate of 86% in preventing COVID-19 infection.